Bioavailability and Bioequivalence Study of Ziftomenib in Participants with Relapsed/Refractory AML or MDS
Sponsor: Kura Oncology Inc.
Phase:
Disease: Acute myeloid leukemia, Myelodysplastic syndrome
EU trial number: 2025-524332-19-00
Population: Patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome undergoing an assessment of the bioavailability and bioequivalence of ziftomenib.
Register Investigator Interest
Interested in offering this trial to suitable patients?